Skip to main content
Premium Trial:

Request an Annual Quote

High Throughput Genomics Raises $10M in First Tranche of Series C Round

NEW YORK (GenomeWeb News) — High Throughput Genomics has pocketed $10 million in a first tranche of Series C financing, the Tucson, Ariz.-based company said yesterday.
HTG, which provides microplate-based gene expression assay technology and services to drug makers, said it will use the cash to expand research and product development efforts in the areas of molecular diagnostics and proteomics, and to build out its commercialization team.
HTG's qNPA technology is used in quantitative, multiplexed, gene-based drug-discovery programs, including target validation, high-throughput screening lead optimization, metabolism, toxicology, and clinical development.
According to the company, its ArrayPlate lysis-only qNPA platform enables scientists to test any sample, including fixed tissues, while avoiding the need for extraction or target amplification.
The financing came from three existing and one new venture capital investor. Leading the tranche was Merck Capital Ventures, with additional investments coming from Solstice Capital, Valley Ventures, and Arcturus Capital, a first-time stakeholder in HTG.
As part of the deal, Solstice Capital’s managing partner, Harry George, will become HTG’s chairman. George has been a member of HTG's board since 2002.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.